Outputs (4)

Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum (2021)
Journal Article
Nakafero, G., Grainge, M. J., Card, T., Taal, M. W., Aithal, G. P., Zhang, W., Doherty, M., Fox, C. P., Mallen, C. D., & Abhishek, A. (2022). Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum. Rheumatology, 61(7), 2783-2791. https://doi.org/10.1093/rheumatology/keab790

OBJECTIVE: To develop and validate a prognostic model for LEF discontinuation with abnormal blood test results. METHODS: Data from the Clinical Practice Research Datalink Gold and Aurum were used for model development and external validation, respect... Read More about Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum.

The Effect of Covid-19 on Alcohol Use Disorder and the Role of Universal Alcohol Screening in an Inpatient Setting: A Retrospective Cohort Control Study (2021)
Journal Article
Subhani, M., Sheth, A., Unitt, S., Aithal, G. P., Ryder, S. D., & Morling, J. R. (2022). The Effect of Covid-19 on Alcohol Use Disorder and the Role of Universal Alcohol Screening in an Inpatient Setting: A Retrospective Cohort Control Study. Alcohol and Alcoholism, 57(2), 203-210. https://doi.org/10.1093/alcalc/agab059

Aim: To assess the impact of Covid-19 on alcohol use disorders (AUD) and the role of universal alcohol screening (UAS) in an inpatient setting. Methods: Retrospective cohorts were defined as pre-pandemic and pandemic admitted to Nottingham University... Read More about The Effect of Covid-19 on Alcohol Use Disorder and the Role of Universal Alcohol Screening in an Inpatient Setting: A Retrospective Cohort Control Study.

Estimating the clinical prevalence of Wilson’s disease in the UK (2021)
Journal Article
Wijayasiri, P., Hayre, J., Nicholson, E. S., Kaye, P., Wilkes, E. A., Evans, J., Aithal, G. P., Jones, G., Pearce, F., & Aravinthan, A. D. (2021). Estimating the clinical prevalence of Wilson’s disease in the UK. JHEP Reports, 3(5), Article 100329. https://doi.org/10.1016/j.jhepr.2021.100329

Background and Aim
The clinical prevalence of Wilson’s disease (WD) in the UK remains unknown. The estimated genetic prevalence in the UK, 142/million, is higher than the clinical prevalence (15/million) reported in other European studies. The aim o... Read More about Estimating the clinical prevalence of Wilson’s disease in the UK.

What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline? (2021)
Journal Article
Nakafero, G., Grainge, M. J., Card, T., Mallen, C. D., Zhang, W., Doherty, M., Taal, M. W., Aithal, G. P., & Abhishek, A. (2021). What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline?. Rheumatology, 60(12), 5785-5794. https://doi.org/10.1093/rheumatology/keab254

Objectives: To examine incidence of treatment changes due to abnormal blood-test results and, to explore rates of treatment changes due to liver, kidney and haematological blood-test abnormalities in autoimmune rheumatic diseases (AIRD) treated with... Read More about What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline?.